Claim review, testimonial handling, patient data, and documentation for cash-pay practices. Built so your marketing survives a close reading.
Overview
Regenerative Medicine Marketing Compliance, In Practice.
Regenerative medicine marketing compliance is the work of making sure everything your practice publishes holds up when read closely: website copy, ad accounts, social captions, email, intake forms, and the reviews already sitting under your name.
For most businesses that means honest advertising. Your practice is a different case. Many of the cell and tissue products marketed directly to patients in this space are not approved by the FDA for the uses being advertised, so one word in a subheading turns a careful page into a claim. What regenerative medicine clinics can and cannot say maps the general shape.
Regen Portal is a marketing company, not a law firm, so consult qualified legal counsel for your specific situation. What we do is narrower: we show you where the lines generally sit, point at the copy closest to them, and hand you a rewrite. Your counsel decides what is right for you.
Primary Sources Only
Your Counsel Decides
The Exposure
Where Clinic Marketing Creates Risk.
Almost none of the exposure we find was put there on purpose. It drifts one word at a time: a therapy being studied becomes a therapy that helps, then a therapy that treats a named condition. Since many products here are not FDA approved for the uses advertised, that last step is the one that matters. The words that create the most exposure covers the pattern.
The rest sits outside the copy. Testimonials get published without mentioning the material connection the FTC asks about. Intake forms collect symptom detail nobody needs to book a consult. Tracking scripts sit on condition pages and pass that visit outward, where HIPAA and marketing meet. We cover both in growing reviews without violating the rules and HIPAA in the funnel.
A Treatment Claim Becomes A Disease Claim
A line about what a therapy is studied for turns into a line about what it treats, usually in a subheading nobody thinks of as copy.
Before And After Says It For You
A gallery makes the promise the copy above it was careful not to make. Nothing claims a result and every visitor reads one anyway.
Reviews With Something Behind Them
A testimonial collected in exchange for anything of value, published with no mention of it. The words are the patient’s. Publishing them is your call.
Intake Forms That Ask Too Much
A form asking about symptoms, diagnoses, and prior procedures before anyone has booked. Every extra field is information you have to protect.
Tracking On Condition Pages
A script on a page about a specific condition, handing that visit to an outside platform. Nobody chose it. It came with the template.
Copy Nobody Owns Anymore
Old landing pages, retired ad variants, and a service page written by a vendor who moved on. Still live, still indexed, still yours.
The Four Systems We Review.
Every engagement touches the same four systems, in the order that carries the most exposure. Claims first, then reviews, then patient data, then the record of what was decided and why. Each ends with a written process, because an undocumented decision gets made differently next time.
AI search raised the stakes without changing the work. Assistants read your pages and repeat what they find in an answer the patient may never click. There is no separate discipline to buy for that: Google’s own guidance says AI-specific markup, llms.txt files, and content chunking are not used. The copy is what gets quoted, so the copy is what we fix.
01.
Claims Review
Every line describing what a therapy does, read against what the product actually is, then rewritten to say the true thing clearly.
02.
Testimonials And Reviews
How you ask, what you publish, what gets disclosed, and who checks, written down so it stops depending on whoever has the inbox.
03.
Patient Data And Intake
What your forms collect, where it goes, and what your site loads on condition pages. Most of the exposure here was installed by default.
04.
Documentation
A record of what was reviewed, what changed, and what your counsel approved, kept current so the answer exists before anybody asks.
What We Do
What Actually Lands In Your Practice.
A Full Marketing Inventory
Every live page, ad, caption, email, and form in one list. Most practices have never seen the whole footprint at once.
Findings, Claim By Claim
Each phrase carrying exposure, pulled out with the reason it was flagged, so nothing rests on a feeling that a page seems risky.
A Lower Risk Rewrite For Each One
Not a list of red flags. A replacement sentence you can publish, written to keep the persuasion and drop the exposure.
A Testimonial And Review Process
How to ask, what to disclose, and what never gets posted, so your front desk is not deciding it live.
Intake Forms Trimmed To What You Need
Fields cut back to what actually books the consult, so you stop collecting information you have to protect.
A Tracking And Analytics Pass
What loads on which page and what leaves your site, so measurement stops carrying condition detail.
Ad And Landing Page Review
The copy that gets read hardest, checked before a disapproval takes a working account down with it.
A Documented Trail
What was reviewed, what changed, and when. The file you hand your counsel instead of rebuilding it from memory.
A Team Briefing
A working session so the people writing captions and answering messages know the line before they post.
Who Sets The Rules
Four Rulebooks, Not One.
The FDA looks at what a product is and what it is approved to do. Cell and tissue products sit in a category the agency regulates directly, and which regulatory pathway a product falls under changes what may be said about it. That classification comes from the product and how it is used, not from the marketing. The difference between the two pathways is worth reading first.
The FTC looks at advertising and endorsements. Its guidance is plain: a material connection behind an endorsement should be disclosed, which reaches anything of value offered for a review, a paid partnership, or a staff member’s family leaving one. Its position on AI and endorsements follows the same logic.
HIPAA reaches marketing twice. There is what patient information may be used for, and separately what has to be done to safeguard it, which is where forms, analytics, and vendors live. States have also written their own rules for stem cell and exosome marketing, and licensing boards apply their own advertising standards to clinicians, so what holds in one state may not hold in the next. The state by state picture keeps moving. Where these lines fall for your practice is your counsel’s call, not ours.
FDA: What The Product Is
What a product is and what it is approved to do decide what may be said about it, and that is settled before a marketer is involved.
FTC: What Sits Behind A Review
Endorsements and testimonials carry a disclosure question. If anything of value changed hands, the reader is meant to see it.
HIPAA: Using Patient Information
Marketing use of patient information is limited and generally turns on the patient’s authorization. Most teams learn that after building the list.
HIPAA: Protecting Patient Information
Separate from what it may be used for is what you do to protect it. Forms, analytics, and every vendor touching that data are in scope.
States And Licensing Boards
States now write their own rules for this category, and boards apply advertising standards to licensed clinicians. It varies by state.
Your Counsel Draws The Line
We show you where the lines generally sit and what the sources say. Where they fall for your practice is a legal question for your attorney.
How A Compliance Review Runs.
Four steps: review, flag, fix, document. We start with the surfaces carrying the most exposure, usually the ad accounts and the service pages naming a specific product. Findings reach you as they land, not in one pile at the end.
Scope depends on how many service lines, live pages, and accounts exist, and how much is already written down, so cost gets scoped in discovery instead of quoted as a number that will not hold. The review touches the rest of the stack as it goes, since the website, the content, and the ad spend all publish claims, and each channel leaves a different amount of room to explain one.
01.
Review
Every live surface read line by line: pages, ads, captions, email, forms, and published reviews.
02.
Flag
Each item carrying exposure, marked with the reason and the source behind it, ranked so the sharpest edges come first.
03.
Fix
A replacement written for every flagged item, so you approve a rewrite instead of a problem with no answer attached.
04.
Document
What was found, what changed, when, and who signed off, kept current so the file is ready before anybody asks.
Common Questions
Marketing Compliance Questions We Get Asked.
The audit is where most practices start. We read everything you have live now, the site, ad accounts, social, email, forms, and published reviews, then show you what carries exposure, why, and what to fix first. You keep the findings whether or not you hire us.
The quote is for practices that already know what needs rewriting and want scope and cost. What it takes depends on how many pages, accounts, and service lines are in play, so pricing gets scoped in discovery rather than posted as a number.
Rarely. Most of what surfaces is a phrase, a form field, or a script, not a strategy. The bulk of your marketing usually stays as it is while a short list of items gets rewritten, often into something better.
Both, plus social captions, email templates, intake forms, and published reviews. Ad accounts carry the most exposure per word, since the copy is short and one disapproval can take the account with it. How we run paid media covers that.
Practices do, with a process behind it. Two questions decide it: what the testimonial claims and what sits behind it. The FTC expects a material connection to be disclosed when anything of value changed hands, and a story describing a specific outcome reads as a claim about the therapy. Growing reviews without violating the rules covers the asking side.
It can be. A tracking script on a page about a specific condition hands that visit outward even with no name attached, and safeguarding patient information is its own obligation. What is safe to measure covers the practical version.
It depends where you practice and where you advertise, and the list of states writing their own stem cell and exosome marketing rules keeps growing. Boards add advertising standards for clinicians on top. We track the state picture, and your counsel confirms what applies.
Carefully. AI writes in the confident voice of general health content, which is the voice that produces a disease claim, and bulk AI output is a named Google spam violation rather than a shortcut. The workflow that holds up uses AI for structure and a person for claims, as in drafting compliant regen content with AI.
That is the intended arrangement. We do the reading, the flagging, and the rewriting, then hand your attorney an organized file instead of a folder of screenshots. Legal sign off stays with them.
WHY REGEN PORTAL
We Learned These Rules Inside The Industry.
Regen Native
Everything Documented
Most agencies meet these rules for the first time on your account, arriving with a health playbook built for insurance-driven practices. It breaks the moment the product is one the market cannot advertise freely.
We came out of regenerative medicine and have worked in it for 15 years. That is why the compliance conversation happens before the campaign instead of after a disapproval, and why every position here points at the agency that published the rule.
We work in one industry. The claim patterns, the state rules, and the questions cash-pay patients ask are the ones we have handled for 15 years.
Every position we take points at the body that published it. If we cannot show you where a rule comes from, we say so.
We do not run this work for two competing practices in the same market. What we write for you stays yours.
The findings, the rewrites, and the documentation are yours to keep, whatever happens to any agency relationship.